| Literature DB >> 28272365 |
Youn-Hwan Hwang1, Hye Jin Yang2, Jin Yeul Ma3.
Abstract
In traditional oriental medicine, Angelica dahurica Radix (ADR) is used in the treatment of gastrointestinal, respiratory, neuromuscular, and dermal disorders. We evaluated the pharmacokinetic profiles of oxypeucedanin, imperatorin, and isoimperatorin, major active ingredients of ADR, in normal and 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis rats. A rapid, sensitive, and validated UPLC/MS/MS method was established for evaluating the pharmacokinetics of three furanocoumarins. After oral administration of ADR (0.5 and 1.0 g/kg), blood samples were collected periodically from the tail vein. In colitis rats, the time to reach the peak concentration (Tmax) of imperatorin and isoimperatorin was significantly delayed (p < 0.05). Lower peak plasma concentrations (Cmax) and longer mean residence times for all furanocoumarins were also observed (p < 0.05) compared with normal rats. There was no significant difference in the area under the plasma concentration-time curve or elimination half-lives. Thus, the delayed Tmax and decreased Cmax, with no influence on the elimination half-life, could be colitis-related changes in the drug-absorption phase. Therefore, the prescription and use of ADR in colitis patients should receive more attention.Entities:
Keywords: Angelica dahurica Radix; colitis; imperatorin; isoimperatorin; oxypeucedanin; pharmacokinetics
Mesh:
Substances:
Year: 2017 PMID: 28272365 PMCID: PMC6155430 DOI: 10.3390/molecules22030416
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1PRM chromatogram of the analytes and internal standard (IS) in plasma: (A) blank plasma; (B) spiked blank plasma in LLOQ; (C) plasma sample after oral administration of Angelica dahurica Radix.
Figure 2Mass spectrum of the analytes and internal standard (IS). Production m/z transitions for oxypeucedanin (A); imperatorin (B); isoimperatorin (C); and warfarin (IS, D) were selected 287.09088 → 203.03345, 271.09573 → 203.03336, and 309.25220 → 163.03865, respectively.
Linearity and calibration curves of oxypeucedanin, imperatorin, and isoimperatorin.
| Component | Range (ng/mL) | Linear Regression Equation | Correlation Coefficient | LLOQ (ng/mL) |
|---|---|---|---|---|
| Oxypeucedanin | 1.0–200 | 0.9996 | 1.0 | |
| Imperatorin | 1.0–200 | 0.9994 | 1.0 | |
| Isoimperatorin | 1.0–200 | 0.9995 | 1.0 |
Accuracy and precision of oxypeucedanin, imperatorin, and isoimperatorin in rat plasma.
| Components | Nominal Concentration (ng/mL) | Intra-Day ( | Inter-Day ( | ||||
|---|---|---|---|---|---|---|---|
| Measured Concentration (ng/mL) | RE (%) | RSD (%) | Measured Concentration(ng/mL) | RE (%) | RSD (%) | ||
| Oxypeucedanin | 2 | 2.1 ± 0.2 | 6.8 | 9.4 | 2.1 ± 0.2 | 6.8 | 8.1 |
| 50 | 49.8 ± 1.7 | −0.7 | 3.4 | 49.1 ± 2.6 | −3.7 | 5.3 | |
| 150 | 152.4 ± 6.5 | 1.6 | 4.3 | 149.1 ± 1.9 | −0.2 | 1.3 | |
| Imperatorin | 2 | 1.9 ± 0.2 | −6.9 | 8.3 | 1.9 ± 0.2 | −4.9 | 8.7 |
| 50 | 49.4 ± 1.9 | −2.2 | 3.9 | 49.9 ± 2.3 | −0.5 | 4.5 | |
| 150 | 149.1 ± 5.7 | −0.6 | 3.8 | 151.7 ± 4.7 | 1.2 | 3.1 | |
| Isoimperatorin | 2 | 1.9 ± 0.1 | −5.1 | 7.0 | 2.0 ± 0.1 | −4.1 | 4.4 |
| 50 | 50.3 ± 1.8 | 1.0 | 3.6 | 48.6 ± 1.3 | −5.6 | 2.8 | |
| 150 | 150.2 ± 3.0 | 0.1 | 1.9 | 151.4 ± 2.7 | 0.9 | 1.8 | |
Extract recovery, matrix effects, and stability of oxypeucedanin, imperatorin, and isoimperatorin in rat plasma.
| Components/Nominal Concentration (ng/mL) | Recovery (%) | Matrix (%) | Stability (%) | ||
|---|---|---|---|---|---|
| Free-Thaw Cycles | At −70 °C for 30 Days | At Room Temperature for 24 h | |||
| Oxypeucedanin | |||||
| 2 | 97.4 ± 7.9 | 100.2 ± 6.7 | 94.4 ± 6.4 | 97.7 ± 6.3 | 94.7 ± 7.6 |
| 50 | 84.6 ± 7.6 | 99.9 ± 2.2 | 99.9 ± 4.3 | 98.0 ± 0.8 | 97.8 ± 3.6 |
| 150 | 77.6 ± 7.4 | 100.8 ± 2.1 | 95.0 ± 8.8 | 99.6 ± 1.4 | 97.8 ± 6.6 |
| Imperatorin | |||||
| 2 | 84.9 ± 9.8 | 91.8 ± 7.6 | 97.4 ± 7.1 | 99.0 ± 6.4 | 97.6 ± 7.8 |
| 50 | 83.4 ± 3.7 | 92.3 ± 2.0 | 100.2 ± 3.3 | 101.0 ± 3.7 | 100.9 ± 5.0 |
| 150 | 79.8 ± 4.2 | 85.2 ± 3.1 | 101.1 ± 3.8 | 94.9 ± 9.7 | 101.6 ± 1.6 |
| Isoimperatorin | |||||
| 2 | 85.3 ± 12.2 | 94.9 ± 12.9 | 101.2 ± 4.6 | 98.3 ± 6.5 | 95.9 ± 7.4 |
| 50 | 75.6 ± 4.7 | 96.2 ± 6.9 | 98.8 ± 3.3 | 98.6 ± 3.6 | 100.3 ± 5.2 |
| 150 | 70.3 ± 7.6 | 94.6 ± 7.7 | 95.6 ± 9.2 | 97.1 ± 6.3 | 97.5 ± 7.2 |
Comparison of the developed method and the previous method for determination of three furanocoumarins.
| Methods | LC/MS/MS | LC/MS/MS | GC-MS | UPLC-MS/MS |
|---|---|---|---|---|
| LLOQ (ng/mL) | ||||
| Oxypeucedanin | 1.16 | 5.00 | 7.00 | 1.00 |
| Imperatorin | 0.14 | 5.00 | 1.00 | |
| Isoimperatorin | 0.14 | 4.00 | 10.00 | 1.00 |
| Plasma sample amount (μL) | 300 | 50 | 200 | 50 |
| Run time (min) | 27.0 | 5.5 | 50.0 | 6.0 |
| Flow rate (mL/min) | 1.0 | 0.3 | 1.2 | 0.3 |
Figure 3TNBS-induced experimental colitis in rats. (A) Macroscopic appearance of normal and damaged colon; (B) Weight of explanted colon.
Figure 4Plasma concentration–time curves of oxypeucedanin (A); imperatorin (B); and isoimperatorin (C) after oral administration of Angelica dahurica Radix (ADR, 0.5 and 1.0 g/kg, open and closed symbols, respectively) to normal (circle) and experimental colitis (square)-induced rats.
Pharmacokinetic parameters of oxypeucedanin, imperatorin, and isoimperatorin after oral administration of Angelica dahurica Radix to normal and experimental TNBS-treated rats.
| Parameters | Normal | TNBS-Treated | ||
|---|---|---|---|---|
| 0.5 g/kg | 1.0 g/kg | 0.5 g/kg | 1.0 g/kg | |
| t1/2 (min) | 78.1 ± 7.5 | 73.5 ± 7.8 | 91.9 ± 44.8 | 72.9 ± 7.7 |
| Tmax (min) | 43.2 ± 11.2 | 49.1 ± 11.0 | 54.0 ± 22.8 | 42.4 ± 14.3 |
| Cmax (ng/mL) | 38.5 ± 1.6 | 101.2 ± 21.2 | 29.0 ± 4.0 * | 61.2 ± 11.9 * |
| AUC0→∞ (min·ng/mL) | 5753.4 ± 649.8 | 10,866.7 ± 1720.6 | 7745.0 ± 1576.0 | 13,126.2 ± 2382.3 |
| MRT (min) | 125.9 ± 13.6 | 118.9 ± 11.0 | 203.7 ± 54.2 * | 175.7 ± 7.8 * |
| t1/2 (min) | 59.5 ± 7.2 | 61.5 ± 6.8 | 65.2 ± 11.5 | 56.1 ± 13.9 |
| Tmax (min) | 54.0 ± 7.7 | 72.0 ± 6.7 | 113.7 ± 13.4 * | 127.1 ± 18.4 * |
| Cmax (ng/mL) | 94.5 ± 19.7 | 201.4 ± 18.8 | 27.7 ± 6.3 * | 118.5 ± 32.5 * |
| AUC0→∞ (min·ng/mL) | 11,860.3 ± 2832.5 | 23,889.0 ± 4003.1 | 5196.0 ± 1349.7 | 24,845.0 ± 6485.8 |
| MRT (min) | 121.1 ± 10.4 | 127.6 ± 11.5 | 172.6 ± 12.8 * | 187.6 ± 9.5 * |
| t1/2 (min) | 63.8 ± 21.9 | 78.1 ± 2.4 | 88.0 ± 12.9 | 68.6 ± 24.2 |
| Tmax (min) | 72.0 ± 6.7 | 67.5 ± 6.3 | 120.0 ± 16.7 * | 144.0 ± 16.3 * |
| Cmax (ng/mL) | 72.1 ± 12.4 | 128.8 ± 8.7 | 21.1 ± 4.9 * | 71.3 ± 16.2 * |
| AUC0→∞ (min·ng/mL) | 9445.4 ± 2157.1 | 17,778.9 ± 2519.3 | 4197.9 ± 919.7 | 17,881.7 ± 4111.3 |
| MRT (min) | 143.2 ± 21.5 | 145.2 ± 11.6 | 204.3 ± 15.2 * | 225.3 ± 33.5 * |
t1/2, elimination half-life; Tmax, time to reach peak concentration; Cmax, peak plasma concentration; AUC0→∞, area under the plasma concentration–time curve from zero to infinity time; MRT, mean residence time. * p < 0.05, compared to normal rats treated with same dose.
Figure 5Chemical structures of oxypeucedanin (A); imperatorin (B); isoimperatorin (C); and warfarin (internal standard, D).
The information of PRM parameters.
| Components | Chemical Formula | Precursor ion [M + H]+ | Production | Normalize Collision Energy | |
|---|---|---|---|---|---|
| Calculated | Measured | ||||
| Oxypeucedanin | C16H14O5 | 287.09140 | 287.09088 | 203.03345 | 35 |
| Imperatorin | C16H14O4 | 271.09649 | 271.09573 | 203.03336 | 20 |
| Isoimperatorin | C16H14O4 | 271.09649 | 271.09619 | 203.03336 | 20 |
| Wafarin (IS) | C19H16O4 | 309.11214 | 309.25220 | 251.06992 | 50 |